Skip to main content
Equibles
ANEB logo

ANEB · Anebulo Pharmaceuticals, Inc.

Track ANEB — free

Use ANEB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANEB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.43 +0.07 (+20.56%) At close · Mar 2
Rebalance outlook locked
Market Cap
$13.46M
Shares
40.78M
Volume · Mar 2 21.4K Avg daily vol (3M) 99.57K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.43 Open$0.35 Day$0.35–0.49 52W close$0.36–3.33 Avg vol 30d108K Short int6K · 0.0% of shares · 6.2d Short vol100% DataMay 2021–Mar 2026 Filing10-Q · Feb 12

Latest documents

2026
Jan 29
Current report 8-K
Other events AI summary on its way
Jan 27
Current report 8-K Events of Jan 26
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$7.98M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$9.04M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+49.9%
Year over year · more shares
Price change (1Y)
-62.6%
Trailing year
Short interest
—
Latest settlement
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.2 · fear Equity put/call 0.89
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −76%
below
Price vs 50-day avg −54%
below
RSI (14) 29
oversold
MACD trend Positive
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −59%
trailing
6-month return −80%
trailing
YTD return −57%
this year
Relative strength −86%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-10% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.01% of shares out · ▬ 0.0% MoM · 6.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
19 holders — mid 3-yr range
Fundamentals
Excellent
EPS growth +22%
Y/Y
Balance sheet $11.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 133%
annualized · 1-yr
Max drawdown −89%
past year
ATR 20.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−76% Bearish
Price vs 50-day avg
−54% Bearish
RSI (14)
29 Neutral
MACD trend
Positive Bullish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-10% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.01% of shares out · ▬ 0.0% MoM · 6.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
19 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 2% Range high $3
vs 200-day avg -76% vs 50-day avg -54%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ANEB
Anebulo Pharmaceuticals, Inc.
this stock
$13.46M -57.0% — — 0.0%
VRTX
Vertex Pharmaceuticals Inc
 $138.71B +20.7% +46.2% 35.2 1.7%
MRNA
Moderna, Inc.
 $96.40B +762.0% +4.3% — 8.2%
REGN
Regeneron Pharmaceuticals, Inc.
 $93.82B +17.2% +20.8% 20.1 2.1%
CSLLY
Csl Ltd
 $67.11B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
19
% held
54.5%
Net QoQ
-11.0K sh
Top holder
22NW, LP
Held Float
View
Short & Settlement
Short Interest
Shares short
5.6K
Days to cover
6.2d
Change
0 sh
View
Short Volume
Short vol %
100%
As of
Aug 19, 2026
Short Total
View
Fails to Deliver
FTD shares
4.3K
Value
$3.8K
As of
Mar 18, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Mar 2, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-8.5M
EPS diluted
$-0.25
View
Filings
SEC Filings
Latest
8-K
Filed
Feb 12, 2026
This year
5
View
Exempt Offerings
Offering
$15.0M
Filed
Dec 31, 2024
View
Earnings & Events
Investor Relations
Latest news
Anebulo Pharmaceuticals Reports S…
Published
Feb 12, 2026
View

Performance

5D 20D 120D MTD YTD
ANEB -0.2% -58.7% -80.3% +20.6% -57.0%
SPY +0.6% -0.8% +5.8% +0.1% +0.7%
vs SPY -0.8% -57.9% -86.1% +20.5% -57.7%
Key facts CIK 1815974 CUSIP 034569103 Visit website Investor relations